← Back to Search

Other

TL-925 Arm for Dry Eye Syndrome

Phase 2
Waitlist Available
Research Sponsored by Telios Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to the end of day 29 (±2 days)

Summary

This trial is testing TL-925 eye drops on people with moderate to severe dry eyes. The goal is to see if these drops can help relieve their symptoms. Participants will use the drops regularly over a period of weeks.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to the end of day 29 (±2 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to the end of day 29 (±2 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change from baseline in corneal and conjunctival staining
Change from baseline in ocular discomfort
Change from baseline visual acuity

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: TL-925 ArmActive Control1 Intervention
TL-925 will be administered OU BID
Group II: Placebo ArmPlacebo Group1 Intervention
Placebo will be administered OU BID

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor
10 Previous Clinical Trials
1,558 Total Patients Enrolled
~40 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top